Beckerman Ziv, Cohen Oved, Agmon Yoram, Bolotin Gil
Department of Cardiac Surgery, Rambam Medical Campus, Haifa, Israel.
Heart Surg Forum. 2013 Apr;16(2):E96-8. doi: 10.1532/HSF98.20121106.
The strategy of transcatheter valve-in-valve implantation into failing mitral and aortic bioprosthetic valves is a documented approach. It allows one to avoid performing a high-risk repeat cardiac surgery in elderly patients with multiple comorbidities. Tricuspid valve-in-valve implantation has been documented only a few times in the literature. We report the case of a 65-year-old woman with a failing bioprosthetic tricuspid valve who had undergone 3 prior open heart operations. We attempted a transatrial transcatheter approach and successfully deployed a 29-mm Edwards Sapien balloon-expandable bioprosthesis into a severely stenotic tricuspid bioprosthesis. This case demonstrates the technical feasibility and safety of this approach.
经导管瓣膜中瓣膜植入术用于功能衰竭的二尖瓣和主动脉生物瓣膜的策略是一种已被记载的方法。它使人们能够避免在患有多种合并症的老年患者中进行高风险的再次心脏手术。三尖瓣瓣膜中瓣膜植入术在文献中仅有少数几次记载。我们报告了一例65岁女性患者,其生物瓣三尖瓣功能衰竭,此前已接受过3次心脏直视手术。我们尝试经心房经导管方法,并成功将一个29毫米的爱德华兹Sapien球囊扩张式生物瓣膜植入严重狭窄的三尖瓣生物瓣膜中。该病例证明了这种方法的技术可行性和安全性。